Dipyrithione
CAS 3696-28-4
Dipyrithione (CAS 3696-28-4) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 5122.491666666667 nM | 24 | - |
| - | IC50 | 4077.9666666666662 nM | 9 | - |
| - | MIC | 8.416666666666666 ug.mL-1 | 6 | - |
| - | AC50 | 2166.2999999999997 nM | 3 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Dipyrithione used for in pharmaceutical contexts?
Dipyrithione (CAS 3696-28-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Dipyrithione?
No adverse-event association or SIDER side-effect rows are rendered for Dipyrithione in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Dipyrithione also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Bispyrithione with EU status "prohibited".
What clinical phase is Dipyrithione in?
Dipyrithione is rendered with ChEMBL max phase 2.